G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance

Alexandra Blake, Magdalena Dragan, Rommel G. Tirona, Daniel B. Hardy, Muriel Brackstone, Alan B. Tuck, Andy V. Babwah, Moshmi Bhattacharya

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor α, progesterone receptor and human epidermal growth factor receptor 2 (HER2). TNBC patients lack targeted therapies, as they fail to respond to endocrine and anti-HER2 therapy. Prognosis for this aggressive cancer subtype is poor and survival is limited due to the development of resistance to available chemotherapies and resultant metastases. The mechanisms regulating tumor resistance are poorly understood. Here we demonstrate that the G protein-coupled kisspeptin receptor (KISS1R) promotes drug resistance in TNBC cells. KISS1R binds kisspeptins, peptide products of the KISS1 gene and in numerous cancers, this signaling pathway plays anti-metastatic roles. However, in TNBC, KISS1R promotes tumor invasion. We show that KISS1 and KISS1R mRNA and KISS1R protein are upregulated in TNBC tumors, compared to normal breast tissue. KISS1R signaling promotes drug resistance by increasing the expression of efflux drug transporter, breast cancer resistance protein (BCRP) and by inducing the activity and transcription of the receptor tyrosine kinase, AXL. BCRP and AXL transcripts are elevated in TNBC tumors, compared to normal breast, and TNBC tumors expressing KISS1R also express AXL and BCRP. Thus, KISS1R represents a potentially novel therapeutic target to restore drug sensitivity in TNBC patients.

Original languageEnglish (US)
Article number46525
JournalScientific reports
Volume7
DOIs
StatePublished - Apr 19 2017
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
G-Protein-Coupled Receptors
Drug Resistance
Breast Neoplasms
Kisspeptins
Neoplasms
Proteins
Breast
Receptor Protein-Tyrosine Kinases
Progesterone Receptors
Estrogen Receptors
Pharmaceutical Preparations
Therapeutics
Neoplasm Metastasis
Drug Therapy
Messenger RNA
Peptides
Survival

All Science Journal Classification (ASJC) codes

  • General

Cite this

Blake, Alexandra ; Dragan, Magdalena ; Tirona, Rommel G. ; Hardy, Daniel B. ; Brackstone, Muriel ; Tuck, Alan B. ; Babwah, Andy V. ; Bhattacharya, Moshmi. / G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance. In: Scientific reports. 2017 ; Vol. 7.
@article{81243edfc3df424cb450cc50c21773c0,
title = "G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance",
abstract = "Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor α, progesterone receptor and human epidermal growth factor receptor 2 (HER2). TNBC patients lack targeted therapies, as they fail to respond to endocrine and anti-HER2 therapy. Prognosis for this aggressive cancer subtype is poor and survival is limited due to the development of resistance to available chemotherapies and resultant metastases. The mechanisms regulating tumor resistance are poorly understood. Here we demonstrate that the G protein-coupled kisspeptin receptor (KISS1R) promotes drug resistance in TNBC cells. KISS1R binds kisspeptins, peptide products of the KISS1 gene and in numerous cancers, this signaling pathway plays anti-metastatic roles. However, in TNBC, KISS1R promotes tumor invasion. We show that KISS1 and KISS1R mRNA and KISS1R protein are upregulated in TNBC tumors, compared to normal breast tissue. KISS1R signaling promotes drug resistance by increasing the expression of efflux drug transporter, breast cancer resistance protein (BCRP) and by inducing the activity and transcription of the receptor tyrosine kinase, AXL. BCRP and AXL transcripts are elevated in TNBC tumors, compared to normal breast, and TNBC tumors expressing KISS1R also express AXL and BCRP. Thus, KISS1R represents a potentially novel therapeutic target to restore drug sensitivity in TNBC patients.",
author = "Alexandra Blake and Magdalena Dragan and Tirona, {Rommel G.} and Hardy, {Daniel B.} and Muriel Brackstone and Tuck, {Alan B.} and Babwah, {Andy V.} and Moshmi Bhattacharya",
year = "2017",
month = "4",
day = "19",
doi = "10.1038/srep46525",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance. / Blake, Alexandra; Dragan, Magdalena; Tirona, Rommel G.; Hardy, Daniel B.; Brackstone, Muriel; Tuck, Alan B.; Babwah, Andy V.; Bhattacharya, Moshmi.

In: Scientific reports, Vol. 7, 46525, 19.04.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance

AU - Blake, Alexandra

AU - Dragan, Magdalena

AU - Tirona, Rommel G.

AU - Hardy, Daniel B.

AU - Brackstone, Muriel

AU - Tuck, Alan B.

AU - Babwah, Andy V.

AU - Bhattacharya, Moshmi

PY - 2017/4/19

Y1 - 2017/4/19

N2 - Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor α, progesterone receptor and human epidermal growth factor receptor 2 (HER2). TNBC patients lack targeted therapies, as they fail to respond to endocrine and anti-HER2 therapy. Prognosis for this aggressive cancer subtype is poor and survival is limited due to the development of resistance to available chemotherapies and resultant metastases. The mechanisms regulating tumor resistance are poorly understood. Here we demonstrate that the G protein-coupled kisspeptin receptor (KISS1R) promotes drug resistance in TNBC cells. KISS1R binds kisspeptins, peptide products of the KISS1 gene and in numerous cancers, this signaling pathway plays anti-metastatic roles. However, in TNBC, KISS1R promotes tumor invasion. We show that KISS1 and KISS1R mRNA and KISS1R protein are upregulated in TNBC tumors, compared to normal breast tissue. KISS1R signaling promotes drug resistance by increasing the expression of efflux drug transporter, breast cancer resistance protein (BCRP) and by inducing the activity and transcription of the receptor tyrosine kinase, AXL. BCRP and AXL transcripts are elevated in TNBC tumors, compared to normal breast, and TNBC tumors expressing KISS1R also express AXL and BCRP. Thus, KISS1R represents a potentially novel therapeutic target to restore drug sensitivity in TNBC patients.

AB - Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor α, progesterone receptor and human epidermal growth factor receptor 2 (HER2). TNBC patients lack targeted therapies, as they fail to respond to endocrine and anti-HER2 therapy. Prognosis for this aggressive cancer subtype is poor and survival is limited due to the development of resistance to available chemotherapies and resultant metastases. The mechanisms regulating tumor resistance are poorly understood. Here we demonstrate that the G protein-coupled kisspeptin receptor (KISS1R) promotes drug resistance in TNBC cells. KISS1R binds kisspeptins, peptide products of the KISS1 gene and in numerous cancers, this signaling pathway plays anti-metastatic roles. However, in TNBC, KISS1R promotes tumor invasion. We show that KISS1 and KISS1R mRNA and KISS1R protein are upregulated in TNBC tumors, compared to normal breast tissue. KISS1R signaling promotes drug resistance by increasing the expression of efflux drug transporter, breast cancer resistance protein (BCRP) and by inducing the activity and transcription of the receptor tyrosine kinase, AXL. BCRP and AXL transcripts are elevated in TNBC tumors, compared to normal breast, and TNBC tumors expressing KISS1R also express AXL and BCRP. Thus, KISS1R represents a potentially novel therapeutic target to restore drug sensitivity in TNBC patients.

UR - http://www.scopus.com/inward/record.url?scp=85017657664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017657664&partnerID=8YFLogxK

U2 - 10.1038/srep46525

DO - 10.1038/srep46525

M3 - Article

C2 - 28422142

AN - SCOPUS:85017657664

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 46525

ER -